Rani Therapeutics, LLC

Rani Therapeutics has entered a research agreement with Chugai Pharmaceutical to evaluate the application of its RaniPill® oral delivery technology for Chugai's antibodies against undisclosed targets.

Rani Therapeutics demonstrated that RT-114, an oral GLP-1/GLP-2 dual agonist delivered via RaniPill® capsule, achieved 111% bioavailability compared to subcutaneous injection in preclinical studies, with comparable weight loss outcomes.